An interventional study of Vitrectomy with ILM peeling in Retinal Detachment, sponsored by Al-Azhar University. Active, not recruiting at 1 site in Egypt. Open to participants aged 15 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-01-08.
Sponsored by Al-Azhar University · Not applicable, Interventional, and Treatment
Retinal detachment (RD) resulting from the macular hole (MH), also known as MH-induced RD (MHRD), most commonly occurs in eyes with high myopia and results in irreversible visual disorders. Although ILM peeling for MHRD reportedly achieves a high retinal reattachment rate that ranges from 70% to 100%, the MH closure rate is relatively low, ranging from 10% to 70%.
199 studies on the registry are indexed under Retinal Detachment; 29 are open to participants now.
This study's enrollment of 13 is below the median of 50 across 132 interventional studies indexed under Retinal Detachment.
Browse Retinal Detachment studies →Al-Azhar University is the lead sponsor of 531 studies on the registry; 172 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Procedure: Vitrectomy with ILM peeling
Vitrectomy with traditional internal limiting membrane (ILM) peeling technique is regarded as the gold standard treatment for MH; it works by completely relieving of the traction of the macula and increasing the flexibility of the retina
Closure of macular hole
It is a subjective outcome measured by Optical coherence tomography and by clinical slit lamb examination
Time frame: 6 months post operative
BCVA
It is a measure of the visual acuity, which will be measured by LogMar
Time frame: baseline
BCVA
It is a measure of the visual acuity, which will be measured by LogMar
Time frame: 6 months postoperative
BCVA
It is a measure of the visual acuity, which will be measured by LogMar
Time frame: 12 months postoperative
Plan to share: No
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.